Neoplasms

Blood and Lymph Conditions

All Conditions

Rare Diseases

Polycythemia Vera

Polycythemia

Thrombocytosis

Thrombocythemia, Essential

Hematologic Diseases

Bone Marrow Neoplasms

Hematologic Neoplasms

Bone Marrow Diseases

Myeloproliferative Disorders

Essential Thrombocythemia

Chronic Myeloproliferative Disorders

Pre-filled Syringe, Q2W starting at 250-350-500, SC injection

Pre-filled Syringe, Q2W starting at 100 up to 500 (50mcg increases), SC injection

P1101 (Ropeginterferon alfa-2b-njft)

Ropeginterferon alfa-2b-njft (P1101)

Jewell Jessup, PhD

Poonam Neki

Phil Hutson

Jacob Patterson

Barbie Warner

Leta Ko

Delphine Thomas

Karyn Gordon

Percy Yeung

Noelle Townsend

Mikaela Dougherty

Denise Brigham

Mitchell Davidsz

Suzhen Gong

Nichole Ard

Nicole Fisher

Cory Caldwell

Tathiana Ruiz

Christopher Hillis, PhD

Dana Maassen

Ray Urbanski, MD, PhD

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients with PV

Polycythemia vera (PV) is the most common type of chronic myeloproliferative neoplasm (MPN), with an annual reported incidence of up to 2.6/100,000. This is a long-term debilitating and life-threatening disease because it is associated with the risk of thrombosis, bleeding, and progression to myelofibrosis (MF) and secondary acute myeloid leukemia (sAML)

Ropeginterferon alfa-2b-njft (P1101), which gained US marketing authorization in November 2021, is the only interferon alfa approved for the treatment of PV.

This study aims to evaluate the efficacy, tolerability, and safety of ropeginterferon alfa-2b-njft (P1101) in US and Canadian PV patients, utilizing an optimized dosing regimen.

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

A Phase IIIb, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-njft (P1101) in Adult Patients With Polycythemia Vera (PV)

CHR is defined as hematocrit (HCT) \<45%, white blood cell (WBC) count \<10 × 10\^9/L, platelets (PLT) ≤400 × 10\^9/L in the absence of phlebotomy in the previous 12 weeks.

PharmaEssentia

Spots Global Cancer Trial Database for vera

Every month we try and update this database with for vera cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for vera

Every month we try and update this database with for vera cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for vera cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.